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Introduction: Mammographic density (MD) is one of the strongest determinants of sporadic breast cancer (BC). In
this study, we compared MD in BRCA1/2 mutation carriers and non-carriers from BRCA1/2 mutation-positive families
and investigated the association between MD and BC among BRCA1/2 mutation carriers per type of mutation and
tumor subtype.
Methods: The study was carried out in 1039 female members of BRCA1 and BRCA2 mutation-positive families
followed at 16 Spanish Genetic Counseling Units. Participants’ density was scored retrospectively from available
mammograms by a single blinded radiologist using a 5-category scale (<10 %, 10-25 %, 25-50 %, 50-75 %, >75 %).
In BC cases, we selected mammograms taken prior to diagnosis or from the contralateral breast, whereas, in
non-cases, the last screening mammogram was evaluated. MD distribution in carriers and non-carriers was
compared using ordinal logistic models, and the association between MD and BC in BRCA1/2 mutation carriers
was studied using logistic regression. Huber-White robust estimators of variance were used to take into account
correlations between family members. A similar multinomial model was used to explore this association by BC subtype.
Results: We identified and scored mammograms from 341 BRCA1, 350 BRCA2 mutation carriers and 229 non-carriers.
Compared to non-carriers, MD was significantly lower among BRCA2 mutation carriers (odds ratio (OR) =0.71;
P-value=0.04), but not among BRCA1 carriers (OR=0.84; P-value=0.33). MD was associated with subsequent development
BC (OR per category of MD=1.45; 95 % confidence interval=1.18-1.78, P-value<0.001), with no significant differences
between BRCA1 and BRCA2 mutation carriers (P-value=0.48). Finally, no statistically significant differences were observed
in the association of MD with specific BC subtypes.
Conclusions: Our study, the largest to date on this issue, confirms that MD is an independent risk factor for all BC
subtypes in either BRCA1 and BRCA2 mutation carriers, and should be considered a phenotype risk marker in this context.Introduction
Mammographic density (MD) is one of the strongest
determinants of breast cancer (BC) in most ethnic
groups. In general population studies, higher MD is
consistently associated with a higher BC risk [1]. Individual
variation of MD does not only depend on well-established* Correspondence: mpollan@isciii.es
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status, external hormonal manipulation or body mass
index (BMI), but based on family studies [2–7], it also
depends on the as yet unknown genetic background.
Knowledge of the genetic basis of MD could be a
major milestone in BC risk prediction and prevention.
Previous candidate gene analysis and linkage studies
have shown either inconclusive or discordant results to
date. In contrast, genome-wide association studies have
started to identify some genetic variants that could
explain part of the variation in MD [8]. Furthermore,ccess article distributed under the terms of the Creative Commons Attribution
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are also associated with MD variability [9, 10].
Germline mutations in BRCA1 and BRCA2 genes are
the most frequent cause of strong genetic predisposition
to breast and ovarian cancer. In the last decades, several
studies have evaluated whether the mutational status of
both genes is associated with differences in MD compared
to the general population. Therefore, whereas earlier studies
with limited numbers of patients [11–16] had conflicting
results, two larger and well-conducted studies compared
MD in either affected or healthy BRCA1/2 mutation
carriers [17] and in mutation carriers versus women with
low to average risk [18]. In one of them, authors proved
MD to be an independent risk factor for BC in carriers
[17]. In contrast, findings from a recent study did not reveal
any association between baseline MD and subsequent risk
of BC among carriers [19].
In this paper, we aimed to compare MD in Spanish
BRCA1/2 mutation carriers and non-carriers and assess
the potential impact of MD on subsequent BC risk among
carriers according to the mutated gene and pathologic
subtype.
Methods
A total of 1,039 women were enrolled from 509 breast and
ovarian cancer families who had been counseled and tested
for mutations in BRCA1 and BRCA2 genes, from January
1993 to December 2012, and followed up at 16 Cancer
Genetic Units in Spain. The study was approved by national
and regional Ethics Committees (see Acknowledgments for
details) and conducted in compliance with the Helsinki
Declaration. All women were older than 18 years and gave
written informed consent for the study.
Eligible participants were women from mutation-positive
families, including BRCA1/2 mutation carriers and true
mutation-negative women. Women diagnosed with BC
were considered cases, whereas those individuals with no
personal history of BC were regarded as non-cases or
controls.
Structured questionnaires collecting baseline information
were administered by investigators during either the high-
risk breast screening or the post-test visit. Apart from
demographic characteristics, data for other covariates were
collected, such as the genetic condition, age, weight and
height, reproductive history, menopausal status, the use of
exogenous hormonal supplements and history of risk-
reducing surgery up to the time of the study mammogram.
Controls’ weight and height were measured by the investi-
gator at the enrollment visit. Tumor subtype, weight
and height at the time of the scored mammogram were
extracted from the medical charts of BC patients.
Mammograms were either obtained from the radiological
chart or provided by the participants. Due to the retrospect-
ive design of our study, we considered density measuresfrom analog and digital mammographic films. For cancer
patients, we aimed to collect the earliest mammogram
obtained before diagnosis (within a 10-year period and
identical menopausal status) and excluded the films from
the affected breast. When unavailable, we used the
mammogram of the unaffected contralateral breast
taken at the time of cancer diagnosis. To make the
age of controls at the time of the mammogram more
comparable with those of women with BC, we attempted
to obtain the latest available mammogram. For each par-
ticipant, films from craniocaudal and mediolateral oblique
views were requested. There were 119 women who either
did not have a suitable mammogram (110) or the quality
of the film was insufficient (9), rendering a total of 920
individuals for whom the mammogram was available
and MD reading was feasible. There were 691 women
carrying a deleterious mutation in the BRCA1 or BRCA2
(341 women with BRCA1 and 350 with BRCA2) genes
and 229 women were relatives without a mutation.
Breast density was visually assessed by one experienced
radiologist, with high intra-observer concordance [20].
The radiologist was blinded to the diagnosis, the carrier
status and the referral centre of the mammogram. MD
was classified using the Boyd semiquantitative scale into 6
categories, namely 0 %, <10 %, 10−25 %, 25−50 %, 50−75 %
and >75 %. The radiologist provided a single reading per
participant, considering the craniocaudal and mediolateral
oblique views in both breasts when available. For those
breast cancer cases without previous mammography, the
two views of the contralateral breast were read.
The association between MD and the carrier status as
well as other variables of interest was assessed in healthy
women using an ordinal logistic regression model. This
procedure results from fitting k-1 logistic regression
models, dichotomizing MD into two groups, i.e., high
versus low MD, using all possible cutoffs. This model,
also known as the proportional odds model, assumes
that odds ratios (ORs) remain constant irrespective of
the cutoff chosen, but allows the intercepts to differ.
The following variables were included as possible con-
founders: age at mammogram, BMI, menopausal status
(premenopause/natural menopause/surgical menopause),
parity (nulliparous/parous), type of image (analog/digital)
and carrier status (non-carrier, BRCA1, BRCA2). The
correlation between members of the same family was
taken into account using Huber-White robust estimators
of variance, considering individuals clustered inside
families [21]. The Brant test was used to verify the
proportional odds assumption.
The association between MD and subsequent BC
development was evaluated using a logistic regression
model, adjusted for age at mammogram, menopausal status
(premenopause/natural menopause/surgical menopause),
BMI, parity, age at first live birth, use of hormonal
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time elapsed from mammogram to either BC diagnosis
(cases) or end of follow up (non-cases). The consistency of
the association between MD and BC was explored
performing subgroup analysis in models including MD as a
continuous variable and an interaction term between MD
and each of the explanatory variables already mentioned.
Finally, possible differences in the effect of MD per BC
subtype were assessed using a multinomial logistic model,
adjusted for the same confounders and considering the
following subtypes: 1) hormonal receptor positive (estrogen
receptor (ER) or progesterone receptor (PR)) and human
epidermal growth factor receptor 2 (HER2) negative, 2)
HER2-positive, 3) triple-negative tumors, and 4) unknown
subtype. Again, Huber-White robust estimators of vari-
ance were used in all instances to take into account
the correlation between relatives [21]. Sensitivity analyses
were carried out considering only those cases with
mammograms taken 6 months or more before BC
diagnosis. All statistical analyses were performed by using
the STATA version 12.0 software program (Stata Corp,
College Station, TX, USA).
Results
Baseline characteristics
Baseline characteristics of our population according to
BRCA1/2 mutation carrier status and development of
breast cancer are shown in Table 1. Carriers were younger
at the scored mammogram (mean age was 41 years,
regardless of the mutated gene and disease condition)
compared with non-carriers (45 years; P value <0.001). In
addition, carriers were more likely to have ever used hor-
mone preventive treatment (1.4 % vs 0.4 %; P value = 0.06)
and have undergone surgical menopause at the time of the
selected mammogram (10.3 % vs 1.7 %; P value <0.001).
There were 31 women, 21 BRCA1 and 10 BRCA2
mutation carriers, with a previous diagnosis of ovarian
cancer, and four of them (2 BRCA1 and 2 BRCA2 muta-
tion carriers) subsequently developed a breast tumor.
Among 691 BRCA1/2 mutation carriers, 233 women
developed invasive breast cancer (111 and 122 with
BRCA1 and BRCA2 mutations, respectively), and 15
patients had ductal carcinoma in situ (3 BRCA1 and
12 BRCA2 mutation carriers, respectively), whereas 7
women had invasive breast cancer and the other 3
women developed ductal carcinoma in situ, among
229 non-carriers. Regarding pathologic subtypes, 54
cases, 2 of them among non-carriers, could not be
classified due to lack of information on hormone
receptor expression (11 cases) or HER2 status (54
cases). As expected, BRCA2 mutation carriers were
more likely to have hormone receptor positive
tumors and no expression of HER2 (71 % versus 26 %;
P value <0.001), whereas BRCA1 mutation carriers hada higher proportion of triple-negative tumors (66 %
versus 14 %; P value <0.001).
When we looked specifically at BRCA1/2 mutation
carriers, breast cancer patients had a lower BMI compared
to controls, with 92 % of cases versus 85 % of controls
having BMI <30 (P value = 0.03) (Table 1). No differences
were seen in the age at the time of scored mammogram,
but analog mammography was more frequent among
cases (84 % versus 30 %). Finally, MD was higher in
affected carriers, with 33 % of them in the two highest
categories (MD >50 %) as opposed to 22 % of controls
(P value = 0.001). Menopausal status, parity, age at first
birth, oral contraceptives and hormonal replacement
therapy were not significantly different between both
groups. As expected, surgical menopause was more fre-
quent among controls (14 % versus 4 %; P value <0.001).
Association of mammographic density with other
variables
The association of all categories of mammographic density
and explanatory variables is shown in Table 2. Given the
small number of women with 0 % MD, the two first
categories were combined in subsequent analyses. In
all instances, ORs were adjusted for age at mammo-
gram, BMI, menopausal status (premenopause/natural
menopause/surgical menopause), type of mammogram,
parity, carrier status and subsequent development of BC.
We did not find a significant association between carrying
a BRCA1/2 mutation and a lower MD (OR = 0.77; 95 %
CI = 0.57, 1.05). However, when BRCA1 and BRCA2
mutation carriers were considered separately, BRCA2
mutation carriers had a statistically significant lower MD
(OR = 0.71; 95 % CI = 0.51, 0.98: P value = 0.04), but no
differences were observed for BRCA1 mutation carriers
(P value = 0.332). Most risk factors considered, including
age at mammography, BMI, menopausal status and parity
were, as expected, significantly associated with MD. More-
over, MD was higher among women who subsequently
developed a breast tumor (OR = 1.69; 95 % CI = 1.24,
2.31; P value = 0.001), Finally, neither age at first birth nor
hormonal interventions such as HRT or oral contracep-
tives (OC) significantly modified MD in our study.
Effect of mammographic density in development of
breast cancer in BRCA1/2 mutation carriers
The distribution of MD in BC cases and non-cases for
women who were non-carriers and BRCA1 and BRCA2
mutation-carriers is presented in Fig. 1. Cases tended to
be more frequently classified in the higher MD categories.
Given the limited number of BC cases among the non-
carriers group, we did not evaluate the potential different
effect of MD on cancer risk in non-carriers. Table 3 shows
the association between MD and subsequent development
of BC among BRCA1/2 mutation carriers. After adjusting
Table 1 Characteristics of the women from BRCA1/2 families included in the study
BRCA1/2 mutation carriers Relatives without mutation
Variable Without BC BC patients P valuea Without BC BC patients P valuea
N = 443 N = 248 N = 219 N = 10
Affected gene 0.183 .
BRCA1 227 (51.2 %) 114 (46.0 %)
BRCA2 216 (48.8 %) 134 (54.0 %)
Age at mammography 0.909 0.907
Mean (SD) 41.6 (11.5) 41.5 (10.2) 45.6 (11.8) 45.2 (11.2)
Body mass index 0.030 0.948
<18.5 6 (1.4 %) 7 (2.8 %) 11 (5.0 %) 0 (0.0 %)
18.5−24.9 259 (58.5 %) 151 (60.9 %) 120 (54.8 %) 7 (70.0 %)
25−29.9 110 (24.8 %) 69 (27.8 %) 56 (25.6 %) 2 (20.0 %)
30−34.9 49 (11.1 %) 19 (7.7 %) 28 (12.8 %) 1 (10.0 %)
>=35 19 (4.3 %) 2 (0.8 %) 4 (1.8 %) 0 (0.0 %)
Unknown 0 (0.0 %) 0 (0.0 %) 11 (5.0 %) 0 (0.0 %)
Menopausal statusb 0.239 0.576
Premenopausal 310 (70.0 %) 184 (74.2 %) 147 (67.1 %) 7 (70.0 %)
Postmenopausal 133 (30.0 %) 64 (25.8 %) 72 (32.9 %) 3 (30.0 %)
Type of menopauseb,c <0.001 0.154
Natural 73 (16.5 %) 53 (21.4 %) 69 (95.8 %) 2 (66.7 %)
Surgery 60 (13.5 %) 11 (4.4 %) 3 (4.2 %) 1 (33.3 %)
Time since menopauseb,c 0.100 1.000
<=5 years 31 (7.0 %) 19 (7.7 %) 27 (12.3 %) 1 (10.0 %)
6−10 years 34 (7.7 %) 8 (3.2 %) 17 (7.8 %) 1 (10.0 %)
>10 years 63 (14.2 %) 35 (14.1 %) 28 (12.8 %) 1 (10.0 %)
Unknown 5 (1.1 %) 2 (0.8 %) 0 (0.0 %) 0 (0.0 %)
Nulliparous 0.151 0.264
No 302 (68.2 %) 182 (73.4 %) 167 (76.3 %) 6 (60.0 %)
Yes 141 (31.8 %) 66 (26.6 %) 52 (23.7 %) 4 (40.0 %)
Age at first birth, yearsd 0.110 0.464
>30 75 (16.9 %) 34 (13.7 %) 46 (27.5 %) 0 (0.0 %)
26−30 111 (25.1 %) 64 (25.8 %) 60 (35.9 %) 3 (50.0 %)
21−25 98 (22.1 %) 77 (31.0 %) 53 (31.7 %) 3 (50.0 %)
<=20 18 (4.1 %) 7 (2.8 %) 8 (4.8 %) 0 (0.0 %)
Oral contraceptives 0.487 0.508
No 156 (35.2 %) 81 (32.7 %) 58 (26.5 %) 4 (40.0 %)
Yes 239 (54.0 %) 140 (56.5 %) 130 (59.4 %) 6 (60.0 %)
Unknown 48 (10.8 %) 27 (10.9 %) 31 (14.2 %) 0 (0.0 %)
Use of hormone replacement therapyb 0.613 0.246
No 431 (97.3 %) 238 (96.0 %) 205 (93.6 %) 9 (90.0 %)
Current use 3 (0.7 %) 3 (1.2 %) 5 (2.3 %) 1 (10.0 %)
Past use 9 (2.0 %) 7 (2.8 %) 9 (4.1 %) 0 (0.0 %)
Use of hormonal preventive treatmentb 0.349
No 438 (98.9 %) 243 (98.0 %) 219 (99.5 %) 10 (100 %)
Current use 5 (1.1 %) 5 (2.0 %) 1 (0.5 %) 0 (0.0 %)
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Table 1 Characteristics of the women from BRCA1/2 families included in the study (Continued)
Type of mammogram <0.001 0.020
Analog 132 (29.8 %) 208 (83.9 %) 62 (28.3 %) 6 (60.0 %)
Digital 311 (70.2 %) 40 (16.1 %) 157 (71.7 %) 4 (40.0 %)
Number of projections <0.001 0.069
One 9 (2.0 %) 6 (2.4 %)
Two 34 (7.7 %) 74 (29.8 %) 11 (4.7 %) 3 (25.0 %)
Three 2 (0.5 %) 3 (1.2 %) 1 (0.4 %) 0 (0.0 %)
Four 398 (89.8 %) 165 (66.5 %) 223 (94.9 %) 9 (75.0 %)
Mammographic density 0.001 0.316
0 % 6 (1.4 %) 0 (0.0 %) 3 (1.4 %) 1 (10.0 %)
<=10 % 99 (22.3 %) 35 (14.1 %) 44 (20.1 %) 1 (10.0 %)
11−25 % 89 (20.1 %) 47 (19.0 %) 44 (20.1 %) 2 (20.0 %)
26−50 % 151 (34.1 %) 85 (34.3 %) 72 (32.9 %) 3 (30.0 %)
51−75 % 72 (16.3 %) 47 (19.0 %) 37 (16.9 %) 3 (30.0 %)
>75 % 26 (5.9 %) 34 (13.7 %) 19 (8.7 %) 0 (0.0 %)
Time of follow upe <0.001 0.924
<=1 year 207 (46.7 %) 162 (65.3 %) 103 (47.0 %) 4 (40.0 %)
1−2 years 82 (18.5 %) 30 (12.1 %) 39 (17.8 %) 2 (20.0 %)
2−5 years 94 (21.2 %) 30 (12.1 %) 48 (21.9 %) 3 (30.0 %)
5−10 years 46 (10.4 %) 24 (9.7 %) 22 (10.0 %) 1 (10.0 %)
>10 years 14 (3.2 %) 2 (0.8 %) 7 (3.2 %) 0 (0.0 %)
Prophylatic mastectomy 0.003
No 428 (96.6 %) 248 (100.0 %)
Yes 15 (3.4 %) 0 (0.0 %)
Breast cancer features
Histology .
Ductal in situ 15 (6.0 %) 3 (30.0 %)
Ductal 187 (75.4 %) 6 (60.0 %)
Lobular 12 (4.8 %) 1 (10.0 %)
Medular 14 (5.6 %) 0 (0.0 %)
Others 18 (7.3 %) 0 (0.0 %)
Unknown 2 (0.8 %) 0 (0.0 %)
Type of breast cancer
ER/PR+&HER2− 99 (39.9 %) 6 (60.0 %)
HER2+ 23 (9.3 %) 1 (10.0 %)
Triple-negative 74 (29.8 %) 1 (10.0 %)
Unknown 52 (21.0 %) 2 (20.0 %)
aComparison between women who did and did not develop breast cancer. bAt time of mammography. cOnly postmenopausal women at time of mammography.
dOnly parous women. eTime elapsed from mammographic exploration to breast cancer diagnosis (cases) or last contact (controls). BC breast cancer, ER estrogen
receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
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natural menopause/surgical menopause), parity, age at first
birth, HRT, type of mammogram and time of follow up,
there was a clear association between MD and subsequent
BC development among BRCA1/2 mutation carriers, with
a statistically significant dose-response trend (P value<0.001). The OR in women with density 50−75 % relative
to women with density ≤10 % was 3.24 (95 % CI = 1.43,
7.35; P value = 0.005), while women in the highest MD
category, namely >75 %, had an OR of 4.34 (95 % CI = 1.71,
11.1; P value = 0.002). The association between MD and
BC tended to be stronger among BRCA2 mutation carriers
Table 2 Association of mammographic density with carrier status and other characteristics in healthy female mutation carriers
(controls) from BRCA1/BRCA2 families
Categories of mammographic density
Variable Number <=10 % 11−25 % 26−50 % 51−75 % >75 % Odds ratioa 95 % CIa P value
Carrier status
Non-carrier 219 21 % 20 % 33 % 17 % 9 % 1.00
BRCA1 or BRCA2 443 24 % 20 % 34 % 16 % 6 % 0.75 0.54, 1.04 0.085
BRCA1 227 22 % 25 % 29 % 19 % 6 % 0.84 0.58, 1.23 0.376
BRCA2 216 26 % 15 % 39 % 14 % 6 % 0.67 0.47, 0.96 0.028
Age at mammography, years
<35 188 10 % 14 % 36 % 27 % 13 % 1.00
35−44 199 17 % 19 % 39 % 17 % 8 % 0.94 0.54, 1.62 0.826
45−54 170 29 % 25 % 31 % 12 % 3 % 0.79 0.33, 1.90 0.603
>=55 105 49 % 25 % 24 % 3 % 0 % 0.57 0.15, 2.20 0.415
Linear trend (per year) 0.97 0.95, 0.99 <0.001
Body mass index
<25 396 10 % 17 % 39 % 24 % 10 % 1.00
25.0−29.9 166 36 % 26 % 28 % 7 % 3 % 0.28 0.19, 0.40 <0.001
>=30 100 51 % 24 % 23 % 2 % 0 % 0.16 0.10, 0.25 <0.001
Linear trend (per unit) 0.83 0.80, 0.86 <0.001
Menopausal status & type of menopause
Premenopausal 457 15 % 17 % 37 % 21 % 9 % 1.00
Natural menopause 142 41 % 24 % 28 % 6 % 1 % 0.72 0.45, 1.16 0.179
Surgical menopause 63 38 % 35 % 21 % 6 % 0 % 0.56 0.33, 0.96 0.034
Nulliparous
No 460 29 % 23 % 33 % 13 % 2 % 1.00
Yes 202 9 % 14 % 35 % 24 % 17 % 1.87 1.28, 2.73 0.001
Age at first birth, years (only parous women)
>30 131 25 % 17 % 35 % 17 % 6 % 1.00
25−29 170 25 % 25 % 34 % 15 % 1 % 1.17 0.72, 1.88 0.526
20−24 151 35 % 24 % 30 % 9 % 2 % 1.10 0.67, 1.82 0.706
<20 26 38 % 23 % 27 % 12 % 0 % 0.72 0.31, 1.66 0.436
Linear trend (per year) 1.00 0.97, 1.05 0.745
Hormonal replacement therapy
No 636 23 % 20 % 34 % 17 % 7 % 1.00
Yes 26 23 % 27 % 27 % 15 % 8 % 1.71 0.87, 3.38 0.120
Hormonal preventive therapy
No 656 23 % 20 % 34 % 17 % 7 % 1.00
Yes 6 33 % 17 % 50 % 0 % 0 % 0.67 0.25, 1.82 0.434
Oral contraception
No 214 22 % 18 % 34 % 19 % 7 % 1.00
Yes 369 22 % 21 % 33 % 17 % 7 % 0.93 0.67, 1.27 0.637
Type of image
Analog 194 26 % 21 % 34 % 13 % 6 % 1.00
Digital 468 22 % 20 % 34 % 18 % 7 % 1.09 0.79, 1.50 0.588
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Table 2 Association of mammographic density with carrier status and other characteristics in healthy female mutation carriers
(controls) from BRCA1/BRCA2 families (Continued)
Number of projections
One or two 53 15 % 17 % 40 % 21 % 8 % 1.00
Three or Four 609 24 % 20 % 33 % 16 % 7 % 1.17 0.70, 1.94 0.544
aAdjusted for age at mammogram, body mass index, menopause (premenopausal, natural menopause, surgical menopause), type of mammogram, parity
(nulliparous versus parous ), carrier status (non-carrier, BRCA1, BRCA2) and subsequent development of breast cancer (no, yes)
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BRCA2 and of 1.37 in BRCA1 carriers), but these dif-
ferences were not statistically significant (P value for
heterogeneity = 0.449). Sensitivity analysis including
only the cases with a mammogram obtained at least
6 months before cancer diagnosis had comparable results
(see the central columns in Table 3). Finally, given that
most mammograms from BC cases were analog, the last
columns present the association between MD and BC using
only analog images (Table 3). ORs tended to be stronger in
this case, particularly for BRCA2 mutation carriers. The
analysis of digital images was hampered by the small
number of BC cases available (40 cases: 6 MD <=10 %,
6 MD = 11−25 %, 17 MD = 26−50 %, 9 MD = 51−75 %
and 2 MD >75 %) and no association between MD and BC
was observed (ORs of 1.23, 1.94, 1.88 and 1.22, respectively;
none of the ORs were statistically significant).
The association between MD (as an ordinal variable)
and BC per category of the other explanatory variables
among mutation carriers is presented in Fig. 2. The OR
represents the risk excess associated with an increase inFig. 1 Distribution of mammographic density in breast cancer cases and n
and BRCA2 mutation carriersone category of MD. In general, a consistent effect of
MD on BC risk was seen within all subgroup analyses.
Even though the association seemed to be less marked
among women older than 45 years at the time of
mammography, those who were nulliparous, and those
who had not taken OC, none of these differences were
statistically significant. The smaller number of women
who reported the use of HRT was too small to reach
conclusions in this group. The association with the type of
image was stronger for analog mammograms, but most
cases had analog mammograms, whereas the opposite was
true for non-cases. Finally, MD increased the risk of all
pathologic subtypes BC subtypes in a similar way (P value
for heterogeneity = 0.638).
Discussion
In this case-control study of women from high-risk
breast cancer families, we confirmed that breast density
was an independent risk factor for BC among BRCA1
and BRCA2 mutation carriers. Compared to women with
breast density <10 %, those with densities >50 % had aton-cases in the following groups: non-carriers, BRCA1 mutation carriers
Table 3 Association of mammographic density with subsequent breast cancer in BRCA1/2 mutation carriers
All cases included Excluding cases without a
mammogram taken at least
6 months before diagnosis





ORa 95 % CIa P valuea BC
casesa
ORa 95 % CIa P valuea Non-cases BC
cases
ORb 95 % CIb P valueb
BRCA1+BRCA2
<=10 % 105 35 1.00 12 1.00 36 29 1.00
1125 % 89 47 1.51 0.74, 3.06 0.255 18 1.76 0.70, 4.41 0.228 29 41 1.74 0.72, 4.19 0.216
26−50 % 151 85 1.85 0.90, 3.82 0.095 39 2.26 0.94, 5.44 0.070 45 68 1.77 0.75, 4.15 0.191
51−75 % 72 47 3.24 1.43, 7.35 0.005 21 3.67 1.37, 9.80 0.010 15 38 4.88 1.72, 13.9 0.003
>75 % 26 34 4.34 1.71, 11.1 0.002 17 8.94 2.86, 28.0 <0.001 7 32 9.45 2.73, 32.7 <0.001
Linear trend 443 248 1.45 1.18, 1.78 <0.001 107 1.64 1.28, 2.09 <0.001 132 208 1.68 1.31, 2.15 <0.001
BRCA1
<=10 % 49 15 1.00 3 1.00 15 14 1.00
11−25 % 56 24 2.18 0.85, 5.58 0.103 8 2.71 0.63, 11.7 0.183 15 20 1.78 0.50, 6.48 0.370
26−50 % 66 36 1.90 0.78, 4.67 0.160 14 3.06 0.73, 12.9 0.127 23 30 1.15 0.39, 3.39 0.798
51−75 % 42 22 2.53 0.89, 7.18 0.082 10 4.22 0.93, 19.2 0.063 9 21 3.68 0.75, 18.1 0.109
>75 % 14 17 5.42 1.79, 16.4 0.003 9 12.0 2.20, 65.1 0.004 3 16 7.49 1.57, 35.7 0.012
Linear trend 227 114 1.37 1.06, 1.76 0.015 44 1.65 1.17, 2.32 0.004 65 101 1.51 1.08, 2.12 0.017
BRCA2
<=10 % 56 20 1.00 9 1.00 21 15 1.00
11−25 % 33 23 1.29 0.45, 3.68 0.639 10 1.70 0.47, 6.19 0.419 14 21 2.21 0.76, 6.46 0.146
26−50 % 85 49 2.03 0.65, 6.34 0.222 25 3.36 0.89, 12.7 0.074 22 38 3.85 1.06, 13.9 0.040
51−75 % 30 25 5.37 1.35, 21.4 0.017 11 7.38 1.26, 43.1 0.027 6 17 11.2 1.82, 68.9 0.009
>75 % 12 17 4.82 1.10, 21.1 0.037 8 13.4 2.33, 77.3 0.004 4 16 18.8 3.06, 114.9 0.002
Linear trend 216 134 1.60 1.13, 2.28 0.008 63 1.95 1.30, 2.91 0.001 67 107 2.11 1.40, 3.16 <0.001
aOdds ratio (OR), 95 % CI and P values adjusted for age at mammogram, menopausal status premenopausal, natural menopause, surgical menopause), body mass
index, parity (nulliparous, parous), age at first live birth, use of hormonal replacement treatment (yes, no), type of image (analog, digital) and time elapsed from
mammogram to breast cancer diagnosis (cases) or end of follow up (non-cases). bOR, 95 % CI and P values adjusted for the above-mentioned variables except
type of image
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The association between MD and the risk of subsequent
BC seemed to be stronger for BRCA2 than for BRCA1
mutation carriers, but the sample size was insufficient to
detect statistical differences between them. Our results
also confirmed an association between MD and all
pathologic BC subgroups. Finally, we found that mutation
carriers had lower MD estimations compared to non-
carriers and this difference remained significant among
BRCA2 mutation carriers.
The role of MD as a risk predictor for BC has relevant
implications in screening and preventive interventions,
particularly in highly motivated women with a family
history of the disease. Our results were consistent with
early evidence for the association between BC risk and
MD among women from high-risk families [6, 7] and later
findings on BRCA1 and BRCA2 mutation carriers [17, 18],
assessed by computerized methods for obtaining quantita-
tive measures of MD. Initial case-control studies evaluating
the association between family history, MD and subsequentrisk of BC were completed by Martin et al. [7] in a sample
of 2,322 subjects from three Canadian screening programs.
In that population, MD explained 14 % of the association
between family history and BC risk, being considered an
intermediate marker for BC. Moreover, women with breast
density >50 % had threefold higher risk of BC than those
with <10 % density (95 % CI = 2.17, 4.15). Our OR
for carriers with >50 % breast density are in agreement
with those previously reported in our country among BC
screening attendants, using the same semiquantitative
visual scale [22]. In that study, the risk excess associated
with higher MD was similar in women with and without a
family history of BC, similar to the findings of the Nurses’
Health Study [23].
Raising the question of the potential impact of MD on
women with a germline mutation in BRCA1 and BRCA2
genes, Mitchell et al. evaluated the association between
MD and BC risk among 342 women from the EMBRACE
study, 206 of whom were BRCA mutation carriers [17]. In
spite of some methodological differences and a limited
Fig. 2 Association between mammographic density (MD) and subsequent breast cancer (BC) among BRCA1 or BRCA2 mutation carriers: analysis
stratified by other explanatory variables. Odds ratios (OR) and 95 % CI correspond to an increase in one category of MD. Estimators adjusted for
age at mammogram, menopausal status, body mass index (BMI), parity, age at first live birth, use of hormonal replacement therapy (HRT), type of
image and time elapsed from mammogram to either breast cancer diagnosis (cases) or end of follow up (non-cases). P value reflects the statistical
significance of the interaction term between MD and the corresponding variable in all cases except for BC subtype, for which the P value is for the test
of heterogeneity of the MD effect according to the type of tumor. HPT hormone preventative treatment, ER estrogen receptor, PR progesterone
receptor, HER2 human epidermal growth factor receptor 2
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to ours. Assessing MD with a semi-automatic tool,
the authors estimated the OR for BC among carriers
with ≥50 % breast density to be 2.27 (95 % CI = 0.70, 7.39)
compared with carriers who had <10 % breast density,
while using a qualitative scale (Wolfe’s), the highest density
group had a risk excess close to 3 (OR = 2.78) [17]. In
contrast, a recent prospective nested case-control study
investigating the same issue in a cohort of 462 BRCA
mutation carriers enrolled in a BC screening program
failed to confirm this association [19]. These negative
results could be partially explained by facts such as the
relatively small sample size and small number of cases, the
high proportion of patients with a prior diagnosis and
treatment of BC (19 %), the older mean age at the baseline
mammogram, and the lack of information on BMI, one of
the most important established confounding factors forMD. This confounding effect is particularly relevant when
MD is assessed using computer-assisted tools, given the
strong correlation between BMI and the non-dense area
[24, 25]. Due to the potential impact of cancer treatment
on MD, and similar to the EMBRACE study, we restricted
our study to include only women with first diagnosis
of BC as cases. Indeed, Passaperuma et al. did not
provide information relative to adjuvant cancer therapy,
which could have acted as a confounding factor [19]. In
fact, based on the effect of tamoxifen in reducing MD,
research has been lately focused on evaluating the
potential use of MD variation as a target for identifying
women who would benefit from this drug either as pre-
ventive or adjuvant therapy [26–28].
Despite initial conflicting results from a small series of
patients, two later studies investigating the effect of muta-
tion status on MD patterns have reported similar results.
Ramón y Cajal et al. Breast Cancer Research  (2015) 17:93 Page 10 of 11The first study was based on 505 retrospectively obtained
mammographic readings from 342 women and found no
significant difference in MD between carriers and non-
carriers, either as a group or when mutated genes were
considered separately [17]. In fact, the mean density was
slightly lower in carriers than non-carriers. A second study
compared MD between 143 healthy carriers and 119
women determined to be at low to average risk of BC
[18]. In agreement with our results, the authors also found
a marginally lower, albeit not significant, MD among car-
riers after adjustment for age and BMI. In our study, based
on a larger sample size, mutation carriers had lower breast
density compared to non-carriers, although this effect was
only statistically significant for BRCA2 mutation carriers.
As regards BC subtypes, previous studies have ad-
dressed the association between MD and BC in the
general population with inconsistent results [22, 29–32].
Therefore, whereas a few studies have suggested that MD
is mainly associated with hormone receptor positive
tumors [32], others have reported a similar [22, 30]
or event stronger association with triple-negative tumors,
especially for women aged <55 years [29]. In addition,
and similar to our results in BRCA1/2 mutation car-
riers, a recent study in screening participants in Spain
proved that high MD was associated with all histologic
subtypes of BC [22].
Our study had several limitations, mostly related to its
retrospective nature. Indeed, the heterogeneity of mam-
mograms due to the use of multiple mammographers,
the inclusion of both digital and analog images and dif-
ferences in methodology, such as the subjective visual
assessment of breast density and the use of semiquanti-
tative assessments, limit the comparability of our results
with other studies. Regarding the use of digital and
analog mammograms, density tends to be lower when
estimated via digital mammography and most images for
BC cases were analog (84 % analog versus 16 % digital).
Owing to this, we were able to show a clear effect of
MD on BC risk in general and also restricting the
analysis to cases and controls with analog images, but no
effect was observed using digital mammograms, probably
due to the small number of BCs in this category and the
fact that only eight of them were classified in the extreme
categories. Future studies are needed to confirm these
results in mutation carriers studied with digital mammo-
grams. Last, although the plan in original design of our
study was to use healthy true negative BRCA1/2 mutation
carriers and phenocopies as controls for comparing the
effect of MD on cancer risk between carriers and
non-carriers, the smaller number of cases in this group
did not allow us to accomplish this goal.
The strengths of our study include the fact that this is
the largest cohort of women with a BRCA1/2 mutation and
MD data ever published. In spite of being a multicentricstudy, a single blinded radiologist, who is a highly reputed
expert on mammographic reading, with a very high internal
consistency [20], assessed all mammograms using a
semiquantitative scale that has proved to be associated
with subsequent development of BC [22]. Finally,
restricting the analysis to BC patients with mammograms
obtained 6 months before the diagnosis and the adjust-
ment for all known confounders of MD provides compel-
ling support for our results.
Conclusions
This is the largest study to date to assess the influence
of MD on BC risk and is concordant with previously
published results in that MD is an independent risk factor
among BRCA1/2 mutation carriers. Even though MD was
not increased among mutation carriers compared to
non-carriers, high MD increased the risk of all patho-
logic subtypes of BC. Prospective studies are needed
to clarify the impact of density variations on BC risk and
provide a more pro-active prevention strategy for women
harboring BRCA1/2 mutations.
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